Moschos, S. J., Eroglu, Z., Khushalani, N. I., Kendra, K. L., Ansstas, G., In, G. K., … Abbruzzese, J. L. (2018). NCI 9922: Phase II study of ibrutinib in treatment-refractory distant metastatic cutaneous melanoma (DMCM). In Ann Oncol (Vol. 29 Suppl 8, p. viii453). England. https://doi.org/10.1093/annonc/mdy289.024

Moschos, S. J., Z. Eroglu, N. I. Khushalani, K. L. Kendra, G. Ansstas, G. K. In, P. Wang, et al. “NCI 9922: Phase II study of ibrutinib in treatment-refractory distant metastatic cutaneous melanoma (DMCM).” In Ann Oncol, 29 Suppl 8:viii453, 2018. https://doi.org/10.1093/annonc/mdy289.024.

Moschos SJ, Eroglu Z, Khushalani NI, Kendra KL, Ansstas G, In GK, et al. NCI 9922: Phase II study of ibrutinib in treatment-refractory distant metastatic cutaneous melanoma (DMCM). In: Ann Oncol. 2018. p. viii453.

Moschos, S. J., et al. “NCI 9922: Phase II study of ibrutinib in treatment-refractory distant metastatic cutaneous melanoma (DMCM).” Ann Oncol, vol. 29 Suppl 8, 2018, p. viii453. Pubmed, doi:10.1093/annonc/mdy289.024.

Moschos SJ, Eroglu Z, Khushalani NI, Kendra KL, Ansstas G, In GK, Wang P, Liu G, Collichio FA, Arrowood CC, Reed JE, Garrett-Mead N, Thomas NE, Ollila DW, Ivy SP, Ivanova A, Dees EC, Abbruzzese JL. NCI 9922: Phase II study of ibrutinib in treatment-refractory distant metastatic cutaneous melanoma (DMCM). Ann Oncol. 2018. p. viii453.